View of THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib.

Return to Article Details THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Download Download PDF